levodopa and Weight Gain

Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Diabetes Mellitus, Type 2; Dopamine; Dopamine Agonists; Female; Glucose; Insulin; Insulin-Secreting Cells; Levodopa; Mice; Mice, Inbred C57BL; Obesity; Receptors, Dopamine D2; Sulpiride; Weight Gain

Topics: Aged; Antiparkinson Agents; Body Mass Index; Compulsive Behavior; Dopamine Agonists; Feeding and Eating Disorders; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Weight Gain; Weight Loss

Topics: Adult; Aged; Deep Brain Stimulation; Female; Humans; Impulsive Behavior; Levodopa; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Reward; Subthalamic Nucleus; Weight Gain

Topics: Animals; Dopamine Agents; Eating; Feeding Behavior; Food Preferences; Levodopa; Long-Term Potentiation; Male; Nucleus Accumbens; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Weight Gain

Topics: Aging; Animals; Animals, Newborn; Behavior, Animal; Brain; Diet; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Dopamine; Dopamine D2 Receptor Antagonists; Energy Intake; Fatty Acids; Fatty Acids, Unsaturated; Frontal Lobe; Levodopa; Male; Organ Size; Phosphatidylcholines; Phosphatidylethanolamines; Phosphatidylinositols; Phosphatidylserines; Sulpiride; Swine; Weight Gain

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Animals, Newborn; Basal Ganglia; Brain; Brain Chemistry; Dopamine Agents; Female; Iron; Iron Overload; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinson Disease, Secondary; Prefrontal Cortex; Pregnancy; Weight Gain

Topics: Aged; Antiparkinson Agents; Body Composition; Body Mass Index; Combined Modality Therapy; Dominance, Cerebral; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Energy Metabolism; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome; Weight Gain

Topics: Antiparkinson Agents; Blood Glucose; Blood Proteins; Electric Stimulation; Energy Intake; Energy Metabolism; Fasting; Female; Glucose; Humans; Levodopa; Lipids; Male; Middle Aged; Oxidation-Reduction; Parkinson Disease; Subthalamic Nucleus; Weight Gain

Topics: Activities of Daily Living; Age Factors; Aged; Antiparkinson Agents; Bipolar Disorder; Catechols; Cognition; Combined Modality Therapy; Communication; Deep Brain Stimulation; Dysarthria; Electrodes, Implanted; Emotions; Female; Humans; Levodopa; Male; Middle Aged; Movement; Neuropsychological Tests; Nitriles; Parkinson Disease; Pergolide; Prejudice; Quality of Life; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome; Weight Gain

Topics: Antiparkinson Agents; Basal Metabolism; Body Composition; Calorimetry, Indirect; Deep Brain Stimulation; Eating; Electrodes, Implanted; Energy Intake; Energy Metabolism; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Treatment Outcome; Weight Gain

Topics: Animals; Animals, Newborn; Antipsychotic Agents; Brain Chemistry; Catecholamines; Clozapine; Denervation; Dopamine; Dopamine Agents; Female; Haloperidol; Iron; Iron Overload; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement Disorders; MPTP Poisoning; Norepinephrine; Pregnancy; Psychotic Disorders; Signal Transduction; Weight Gain

Topics: Dyskinesia, Drug-Induced; Eating; Globus Pallidus; Humans; Levodopa; Linear Models; Longitudinal Studies; Motor Activity; Neuropsychological Tests; Nutrition Assessment; Parkinsonian Disorders; Severity of Illness Index; Smell; Stereotaxic Techniques; Surveys and Questionnaires; Weight Gain

Topics: Aggression; Animals; Biogenic Monoamines; Brain; Catecholamines; Dopamine; Levodopa; Social Dominance; Trout; Weight Gain